David P. Sundin

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

Simon Nadel, Brahm Goldstein, Mark D. Williams et al. · The Lancet · 2007 · 499 citations

Severe Sepsis, Pediatrics, Sepsis +5

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation

J. F. Dhainaut, S. Betty Yan, David E. Joyce et al. · Journal of Thrombosis and Haemostasis · 2004 · 427 citations

Thrombosis, Severe Sepsis, Hematology +8

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale et al. · Critical Care Medicine · 2005 · 320 citations

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

Hartmut Porst, Edward D. Kim, Adolfo Casabé et al. · European Urology · 2011 · 174 citations

Urology, International Randomized, Benign Prostatic Hyperplasia +4

Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated)

Marcel Levi, Mitchell M. Levy, Mark D. Williams et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 167 citations